A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2015

Conditions
Glioblastoma Multiforme
Interventions
BIOLOGICAL

ICT-107

Autologous dendritic cells pulsed with immunogenic antigens

BIOLOGICAL

Placebo DC

Autologous dendritic cells (DC) that have not been pulsed with antigens

Trial Locations (25)

10016

NYU Clinical Cancer Center, New York

10065

Weil Cornell Medical College, New York

11021

The Long Island Brain Tumor Center at Neurological Surgery, PC, Great Neck

17033

Penn State Hershey Medical Center, Hershey

19104

University of Pennsylvania, Philadelphia

19107

Thomas Jefferson University, Philadelphia

21287

Johns Hopkins University School of Medicine, Baltimore

22908

University of Virginia Health System, Charlottesville

27157

Wake Forest University, Winston-Salem

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

35294

University of Alabama at Birbingham School of Medicine, South Birmingham

40245

Jewish Hospital Medical Center, Louisville

44106

Case Comprehensive Cancer Center, Cleveland

44195

Cleveland Clinic Rose Ella Burkhardt Brain Tumor and Neuro Oncology Center, Cleveland

60611

Northwestern Memorial Hospital, Chicago

60612

Rush University Medical Center, Chicago

75246

Sammons Cancer Center (Baylor), Dallas

77030

University of Texas Health Science Center at Houston, Houston

85724

Arizona Cancer Center, Tucson

90048

Cedars-Sinai Medical Center, Los Angeles

92093

UC San Diego Moores Cancer Center, La Jolla

02114

Massachusetss General Hospital, Boston

Massachusetts General Hospital, Boston

08818

New Jersey Neuroscience Institute, Edison

08901

Cancer Institute of New Jersey, New Brunswick

Sponsors
All Listed Sponsors
lead

Precision Life Sciences Group

INDUSTRY